Table 2.
Serum biochemical data for male and female BALB/c mice intramuscularly administered the ssRNA nano-structure adjuvant.
| Group 1 | Group 2 | Group 3 | Group 4 | Group 5 | Group 6 | |
|---|---|---|---|---|---|---|
| Male | ||||||
| ALT (U/L) | 53.7 ± 52.5 | 36.0 ± 8.9 | 36.2 ± 3.1 | 32.7 ± 3.5 | 39.1 ± 5.4 | 25.9 ± 4.6 |
| AST (U/L) | 73.0 ± 20.3 | 66.3 ± 9.3 | 67.1 ± 12.6 | 66.5 ± 14.1 | 79.5 ± 15.3 | 51.5 ± 3.6 * |
| BUN (mg/dL) | 31.7 ± 6.4 | 38.5 ± 6.7 | 27.3 ± 3.6 | 32.2 ± 7.1 | 35.3 ± 8.8 | 24.1 ± 1.0 * |
| Creatinine (mg/dL) | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.2 ± 0.1 | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.1 ± 0.0 * |
| TP (g/dL) | 5.8 ± 0.5 | 5.6 ± 0.3 | 5.5 ± 0.3 | 5.5 ± 0.2 | 5.3 ± 0.3 | 5.1 ± 0.5 |
| Albumin (g/dL) | 3.3 ± 0.2 | 3.2 ± 0.3 | 3.2 ± 0.1 | 3.3 ± 0.1 | 3.0 ± 0.1 * | 3.2 ± 0.2 |
| A/G | 1.4 ± 0.2 | 1.3 ± 0.2 | 1.4 ± 0.1 | 1.5 ± 0.1 | 1.4 ± 0.1 | 1.7 ± 0.2 * |
| T-Chol (mg/dL) | 148.0 ± 9.0 | 144.0 ± 18.0 | 154.0 ± 6.0 | 148.0 ± 8.0 | 152.0 ± 16.0 | 146.0 ± 12.0 |
| TG (mg/dL) | 99.0 ± 14.0 | 121.0 ± 33.0 | 125.0 ± 24.0 | 84.0 ± 10.0 | 49.0 ± 21.0 * | 150.0 ± 38.0 * |
| Glucose (mg/dL) | 165.7 ± 21.7 | 200.0 ± 35.5 | 178.2 ± 20.5 | 174.5 ± 22.9 | 122.8 ± 40.3 | 169.2 ± 20.3 |
| HDL (mg/dL) | 113.3 ± 6.2 | 117.1 ± 10.8 | 129.1 ± 7.0 * | 117.3 ± 5.5 | 124.2 ± 13.5 | 106.6 ± 8.2 |
| LDL (mg/dL) | 5.2 ± 1.3 | 5.5 ± 1.0 | 6.2 ± 0.9 | 4.7 ± 0.7 | 6.2 ± 1.1 | 6.2 ± 0.9 |
| Female | ||||||
| ALT (U/L) | 32.6 ± 3.2 | 35.2 ± 5.3 | 29.1 ± 2.6 | 35.5 ± 7.5 | 29.8 ± 2.9 | 35.8 ± 8.5 |
| AST (U/L) | 69.3 ± 6.0 | 76.3 ± 5.9 | 63.9 ± 3.8 | 75.8 ± 11.6 | 63.9 ± 6.4 | 74.3 ± 9.6 |
| BUN (mg/dL) | 26.3 ± 3.4 | 32.6 ± 11.6 | 44.1 ± 6.0 * | 28.8 ± 5.6 | 35.1 ± 4.7 * | 28.0 ± 4.1 |
| Creatinine (mg/dL) | 0.2 ± 0.1 | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.2 ± 0.0 | 0.1 ± 0.0 * |
| TP (g/dL) | 5.9 ± 0.6 | 6.0 ± 0.5 | 5.0 ± 0.4 * | 5.6 ± 0.2 | 5.0 ± 0.4 * | 5.0 ± 0.3 * |
| Albumin (g/dL) | 3.3 ± 0.3 | 3.3 ± 0.2 | 3.1 ± 0.1 | 3.0 ± 0.6 | 3.1 ± 0.1 | 3.2 ± 0.2 |
| A/G | 1.3 ± 0.4 | 1.3 ± 0.3 | 1.7 ± 0.3 | 1.2 ± 0.4 | 1.8 ± 0.5 | 1.8 ± 0.3 |
| T-Chol (mg/dL) | 109.0 ± 17.0 | 105.0 ± 13.0 | 110.0 ± 7.0 | 101.0 ± 23.0 | 109.0 ± 9.0 | 105.0 ± 13.0 |
| TG (mg/dL) | 148.0 ± 18.0 | 109.0 ± 37.0 | 148.0 ± 36.0 | 100.0 ± 22.0 * | 112.0 ± 7.0 * | 130.0 ± 49.0 |
| Glucose (mg/dL) | 165.2 ± 21.0 | 176.5 ± 50.5 | 190.0 ± 37.0 | 196.6 ± 29.4 | 197.7 ± 31.5 | 216.9 ± 9.3 * |
| HDL (mg/dL) | 92.9 ± 4.2 | 92.2 ± 4.1 | 82.4 ± 5.0 * | 91.1 ± 5.5 | 83.9 ± 11.5 | 80.8 ± 10.8 * |
| LDL (mg/dL) | 9.2 ± 0.6 | 9.7 ± 0.8 | 9.6 ± 1.4 | 9.7 ± 0.6 | 9.3 ± 1.4 | 8.1 ± 0.8 * |
The data shown are expressed as the mean ± SD. *p < 0.05, relative to Group 1. Group 1, PBS-control group; Group 2, 1 μg MERS S protein; Group 3, 200 μg ssRNA adjuvant; Group 4, 1 μg MERS S protein and 20 μg ssRNA adjuvant; Group 5, 1 μg MERS S protein and 200 μg ssRNA adjuvant; Group 6, 1 μg MERS S protein and 200 μg ssRNA (recovery group).